At the Intellia Therapeutics, Inc. operational highlights and financial results for the first quarter ended 31 March 2022, President and CEO John Leonard, M.D., says:
“We continue to advance our second in vivo candidate, NTLA-2002, which benefits from the modularity of our platform. We look forward to another important clinical milestone in the second half of this year when we expect to present initial data from the NTLA-2002 first-in-human study. Finally, we remain well-funded to drive forward our robust portfolio and to support continued investment in platform innovation as we build upon our leadership position in genome editing.”
(Source: Intellia)
